Medicine and Dentistry
Surgery
100%
Neoplasm
63%
Vestibular Schwannoma
60%
Meningioma
52%
Facial Nerve
39%
Recurrent Disease
33%
Brain Metastasis
26%
Odds Ratio
24%
Stereotactic Radiosurgery
23%
Skull Surgery
19%
Microsurgery
18%
Aneurysm
17%
Skull Base
17%
Metastatic Carcinoma
15%
Radiation Therapy
14%
Neurosurgery
14%
Surgical Approach
13%
Neurinoma
13%
Systematic Review
13%
Cranioplasty
13%
2 Hydroxyglutaric Acid
13%
Cavernoma
13%
Polyetheretherketone
13%
Sella turcica
13%
Nuclear Magnetic Resonance Spectroscopy
13%
Magnetic Resonance Imaging
12%
Ligation
11%
Headache
11%
Craniotomy
11%
Anatomy
10%
Diagnosis
10%
Overall Survival
10%
Skull Base Tumor
10%
Nerve Function
9%
Clinical Management
9%
Temporal Bone
9%
Sphenoid
8%
Nerve Transplantation
8%
Carcinoma
8%
Brainstem
8%
Surgeon
7%
Facial Nerve Paralysis
7%
Quality of Life
7%
Endoscopic Surgery
7%
Paralysis
7%
Cancer Surgery
7%
Liquorrhea
7%
Surgical Infection
7%
Ganglioglioma
7%
Symptom
6%
Keyphrases
Vestibular Schwannoma
32%
Brain Metastases
26%
Stereotactic Radiosurgery
20%
Surgical Resection
14%
2-Hydroxyglutarate (2-HG)
13%
Facial Nerve Outcome
12%
Resection
12%
Retrospective Review
8%
Tumor
8%
Glioma
7%
Cancer Patients
7%
Patient Management
7%
Clinical Management
6%
Low-grade Glioma
6%
Tumor Volume
6%
Level 1 Trauma Center
6%
Petroclival
6%
Sinonasal Neoplasms
6%
Hearing Preservation
6%
Improved Survival
6%
Clinical Utility
6%
Psammomatoid
6%
Patient-derived Organoids
6%
Transpromontorial Approach
6%
Pituitary Adenoma
6%
Neoadjuvant
6%
Clinical Evaluation
6%
Brain Tumor
6%
Lateral Spread Response
6%
E129
6%
Autologous Cranioplasty
6%
Craniovertebral Junction
6%
Triple Refocusing
6%
Meningioma
6%
Palsy
6%
Transcanal Transpromontorial Approach
6%
Two-level
6%
Recurrence-free Survival
6%
Kidney Cancer
6%
Presigmoid Approach
6%
Temporal Bone Carcinoma
6%
MR Spectroscopy
6%
Foramen Magnum Meningioma
6%
Traumatic Brain Injury
6%
Kadish Stage
6%
Endoscopic Endonasal
6%
Polyetheretherketone Implant
6%
Isocitrate Dehydrogenase 1 (IDH1)
6%
Endoscopic Skull Base Surgery
6%
Evaluating Risks
6%